Abeona Therapeutics Inc. Securities Litigation

If you purchased a significant amount of shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Abeona Therapeutics Inc.
Date Filed:November 1st, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Abeona Therapeutics Inc. was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona is a clinical-stage biopharmaceutical company that purports to develop cell and gene therapies for life-threatening rare genetic diseases.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Abeona's Chemical, Manufacturing and Controls and internal controls and procedures and/or compliance policies were inadequate; (ii) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (iii) consequently, it was foreseeable that the U.S. Food and Drug Administration would reject approval for the start of the VITAL Study until such issues were addressed; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Abeona Therapeutics Inc.

 
First Identified Complaint

Sudipta Majumdar, et al. v. Abeona Therapeutics Inc., et al.

Date Filed:November 1st, 2019
Class Period Start:May 31st, 2018
Class Period End:September 23rd, 2019
First Identified Complaint Filings
#Document TitleFiling Date